326 related articles for article (PubMed ID: 24932597)
41. Somatropin therapy in adults with Prader-Willi syndrome.
Höybye C; Thorén M
Treat Endocrinol; 2004; 3(3):153-60. PubMed ID: 16026111
[TBL] [Abstract][Full Text] [Related]
42. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome.
Carrel AL; Myers SE; Whitman BY; Eickhoff J; Allen DB
J Clin Endocrinol Metab; 2010 Mar; 95(3):1131-6. PubMed ID: 20061431
[TBL] [Abstract][Full Text] [Related]
43. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
[TBL] [Abstract][Full Text] [Related]
44. Three years of growth hormone treatment in young adults with Prader-Willi Syndrome previously treated with growth hormone in childhood: Effects on glucose homeostasis and metabolic syndrome.
Damen L; Grootjen LN; Donze SH; Juriaans AF; de Graaff LCG; van der Velden JAEM; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2020 Oct; 93(4):439-448. PubMed ID: 32609902
[TBL] [Abstract][Full Text] [Related]
45. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
Carrel AL; Allen DB
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1445-51. PubMed ID: 11837498
[TBL] [Abstract][Full Text] [Related]
46. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
Oto Y; Tanaka Y; Abe Y; Obata K; Tsuchiya T; Yoshino A; Murakami N; Nagai T
Am J Med Genet A; 2014 Mar; 164A(3):671-5. PubMed ID: 24443368
[TBL] [Abstract][Full Text] [Related]
47. GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome.
Rigamonti AE; Crinò A; Bocchini S; Convertino A; Bidlingmaier M; Haenelt M; Tamini S; Cella SG; Grugni G; Sartorio A
Growth Horm IGF Res; 2018 Apr; 39():13-18. PubMed ID: 29217318
[TBL] [Abstract][Full Text] [Related]
48. [Prader-Willi syndrome and growth hormone treatment].
Castinetti F; Reynaud R; Brue T
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S6-S10. PubMed ID: 18954862
[TBL] [Abstract][Full Text] [Related]
49. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome.
Lafortuna CL; Minocci A; Capodaglio P; Gondoni LA; Sartorio A; Vismara L; Rizzo G; Grugni G
J Clin Endocrinol Metab; 2014 May; 99(5):1816-24. PubMed ID: 24471571
[TBL] [Abstract][Full Text] [Related]
50. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment.
Festen DA; de Weerd AW; van den Bossche RA; Joosten K; Hoeve H; Hokken-Koelega AC
J Clin Endocrinol Metab; 2006 Dec; 91(12):4911-5. PubMed ID: 17003096
[TBL] [Abstract][Full Text] [Related]
51. [Prader-Willi syndrome. Treatment with growth hormone in 2 cases].
Youlton R
Rev Med Chil; 2001 Oct; 129(10):1186-90. PubMed ID: 11775347
[TBL] [Abstract][Full Text] [Related]
52. Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment.
Höybye C; Barkeling B; Espelund U; Petersson M; Thorén M
Growth Horm IGF Res; 2003 Dec; 13(6):322-7. PubMed ID: 14624765
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
[TBL] [Abstract][Full Text] [Related]
54. Prader-Willi syndrome, diabetes mellitus and hypogonadism.
Nagai T; Mori M
Biomed Pharmacother; 1999 Dec; 53(10):452-4. PubMed ID: 10665337
[TBL] [Abstract][Full Text] [Related]
55. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
[TBL] [Abstract][Full Text] [Related]
56. Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
Grootjen LN; Rutges JPHJ; Damen L; Donze SH; Juriaans AF; Kerkhof GF; Hokken-Koelega ACS
Eur J Endocrinol; 2021 May; 185(1):47-55. PubMed ID: 33886496
[TBL] [Abstract][Full Text] [Related]
57. Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition.
Höybye C
Acta Paediatr; 2015 Apr; 104(4):422-7. PubMed ID: 25557351
[TBL] [Abstract][Full Text] [Related]
58. Early psychomotor development and growth hormone therapy in children with Prader-Willi syndrome: a review.
Jin YY; Luo FH
Eur J Pediatr; 2024 Mar; 183(3):1021-1036. PubMed ID: 37987848
[TBL] [Abstract][Full Text] [Related]
59. Is there growth hormone deficiency in prader-willi Syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in Prader-Willi syndrome.
Eiholzer U; Bachmann S; l'Allemand D
Horm Res; 2000; 53 Suppl 3():44-52. PubMed ID: 10971104
[TBL] [Abstract][Full Text] [Related]
60. Diagnosis and treatment of GH deficiency in Prader-Willi syndrome.
Grugni G; Marzullo P
Best Pract Res Clin Endocrinol Metab; 2016 Dec; 30(6):785-794. PubMed ID: 27974191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
